Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

KaloBios Pharmaceuticals Inc announces preliminary phase 1 results in advanced hematologic malignancies with kb004, an anti-epha3 monoclonal antibody


Tuesday, 10 Dec 2013 09:00am EST 

KaloBios Pharmaceuticals Inc:Says preliminary results of an ongoing multi-center Phase 1 study of KB004, an anti-EphA3 monoclonal antibody (mAb), which the company is developing as a treatment for hematologic malignancies.Says Forty-four patients with refractory disease or who were unfit for chemotherapy have been enrolled in the dose escalation portion of the study.Says experimental patient-targeted therapeutic has been well tolerated, with initial evidence of clinical activity. 

Related Company News

Company Quote

1.53
0.05 +3.38%
29 Aug 2014